Roche Holding AG (OTCMKTS:RHHBY - Get Free Report)'s share price hit a new 52-week high during trading on Tuesday . The stock traded as high as $43.07 and last traded at $42.51, with a volume of 4064198 shares trading hands. The stock had previously closed at $41.83.
Wall Street Analysts Forecast Growth
Several brokerages have commented on RHHBY. Sanford C. Bernstein upgraded shares of Roche to a "strong-buy" rating in a research report on Thursday, January 30th. UBS Group upgraded shares of Roche from a "hold" rating to a "strong-buy" rating in a research report on Thursday, February 13th. Finally, Morgan Stanley initiated coverage on shares of Roche in a research report on Wednesday, February 12th. They issued an "equal weight" rating for the company. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, Roche presently has an average rating of "Moderate Buy".
Read Our Latest Analysis on RHHBY
Roche Price Performance
The company has a debt-to-equity ratio of 0.86, a current ratio of 1.26 and a quick ratio of 0.97. The stock's 50-day moving average is $39.01 and its 200 day moving average is $38.51.
Institutional Trading of Roche
A number of large investors have recently made changes to their positions in RHHBY. Bard Financial Services Inc. increased its position in shares of Roche by 156.8% in the 3rd quarter. Bard Financial Services Inc. now owns 80,500 shares of the company's stock valued at $3,216,000 after buying an additional 49,150 shares in the last quarter. Minot DeBlois Advisors LLC acquired a new position in Roche in the 4th quarter worth $752,000. SVB Wealth LLC acquired a new position in Roche in the 4th quarter worth $555,000. Verity Asset Management Inc. acquired a new position in Roche in the 3rd quarter worth $253,000. Finally, IHT Wealth Management LLC acquired a new position in Roche in the 3rd quarter worth $236,000.
About Roche
(
Get Free Report)
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.
See Also
Before you consider Roche, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roche wasn't on the list.
While Roche currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
